Author

N. A. Lack

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 6

Signature Assays, Organisms & Methods

Click to filter · or open tag

Organism:human· 6 Research Focus:cancer & tumor microenvironment· 3 Research Focus:chromatin & epigenetic regulation· 3 Approach:experimental assay· 3 Research Focus:gene regulatory network inference· 3 Assay:ChIP-seq· 2 Research Focus:differential expression· 2 Approach:genetic perturbation / CRISPR· 2

Frequent Co-Authors

T. Morova· 5 shared S. Lingadahalli· 3 shared T. Bagci-Onder· 3 shared A. C. Aksu· 2 shared A. Cherkasov· 2 shared A. Cingoz· 2 shared B. Gokbayrak· 2 shared C. Collins· 2 shared

Activity by Year

2019-2023 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 35 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

5 shared papersCancer Biology

T. Morova

Mutual co-authors in cluster

Author profile →

6 papers

Recent·Most cited

HOXB13 alters chromatin accessibility in prostate cancer through interactions with the SWI/SNF complex

S. Lingadahalli, B. E. Fazlioglu, U. B. Altintas, A. Cingoz, E. Tekoglu, I. P. L. Yu, H. Andomat, I. Kulac, T. Morova, K. Xiao, U. M. Dikbas, M. Gleave, L. Fazli, P. Cejas, H. Long, , N. A. Lack

This study shows HOXB13 promotes prostate cancer proliferation by altering chromatin accessibility through interactions with the SWI/SNF complex, particularly in AR-negative castration-resistant prostate cancer.

bioRxiv · Sep 4, 2023 · PreprintCancer Biology

Epigenetic-focused CRISPR/Cas9 screen identifies ASH2L as a regulator of glioblastoma cell survival

E. Ozyerli-Goknar, E. Y. Kala, A. C. Aksu, I. Bulut, A. Cingoz, S. Nizamuddin, M. Biniossek, F. Seker-Polat, T. Morova, C. Aztekin, S. H. A. Kung, H. Syed, N. Tuncbag, M. Gonen, M. Philpott, , T. Bagci-Onder

This study uses CRISPR/Cas9 screens to identify ASH2L as a key regulator of glioblastoma cell survival, with downstream effects on cell cycle and apoptosis.

bioRxiv · Aug 17, 2022 · PreprintCancer Biology

EPIKOL, a chromatin-focused CRISPR/Cas9-based screening platform, to identify cancer-specific epigenetic vulnerabilities

O. Yedier-Bayram, B. Gokbayrak, A. C. Aksu, A. D. Cavga, A. Kayabolen, E. Y. Kala, G. Karabiyik, R. Gunsay, T. Morova, F. Uyulur, N. A. Lack, T. T. Onder, T. Bagci-Onder

The paper introduces EPIKOL, a CRISPR-Cas9 library targeting epigenetic modifiers, and demonstrates its utility in identifying cancer-specific epigenetic vulnerabilities in breast and prostate cancer.

bioRxiv · May 14, 2021Cancer Biology

Dynamic phase separation of the androgen receptor and its coactivators to regulate gene expression.

F. Zhang, S. Wong, J. Lee, S. Lingadahalli, C. Wells, N. Saxena, C. Sanchez, B. Sun, A. K. Parra-Nunez, N. Chan, J. M. Bui, Y. Wang, P. S. Rennie, N. A. Lack, A. Cherkasov, , N. Lallous

This study shows that androgen receptor (AR) and its co-activator MED1 form dynamic, AR-rich condensates at superenhancers in prostate cancer, which are crucial for oncogenic gene expression.

bioRxiv · Mar 27, 2021Cancer Biology

Functional mapping of androgen receptor enhancer activity

C.-C. F. Huang, S. Lingadahalli, T. Morova, D. Ozturan, E. Hu, I. P. L. Yu, S. Linder, M. Hoogstraat, S. Stelloo, F. Sar, H. van der Poel, U. B. Altintas, M. Saffarzadeh, S. Le Bihan, B. McConeghy, , N. A. Lack

The paper functionally maps AR enhancer activity using STARRseq, finding most AR binding sites are inactive or constitutively active, with inducible enhancers forming regulatory hubs that drive gene transcription.

bioRxiv · Aug 18, 2020Cancer Biology

Androgen receptor binding sites are highly mutated in prostate cancer

T. MOROVA, M. GÖNEN, A. GÜRSOY, O. KESKIN, N. A. LACK

The paper shows that AR binding sites in prostate cancer have high mutation rates, suggesting they may be driver mutations.

Oncology Abstracts · Sep 26, 2019Peer-reviewedCancer Biology